39P Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): Updated results of a randomized, open-label, phase II trial
作者
Li Su,P. Lin,F. Huang,Ziliang Ye,H. Li,C. Zhuo,S. Wei,S. Yu,Jingjing Li,Sunyi Zheng,Y. Hong,L. Zheng,S. Zhao,Renxi Lin